



## ***Publication of a new letter to shareholders***

**Paris (France), Copenhagen (Denmark), September 30, 2015** – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announces the publication of its new letter to shareholders.

This issue is devoted to our orphan oncology product Beleodaq®. You will find full information about the product, its key features and indications, as well as interviews with medical and scientific experts that highlight the broad potential of this innovative HDAC inhibitor for the treatment of cancer. The letter also provides feedback about the latest analyst meeting held in Paris in September and useful details regarding Onxeo's financial communication.

*The shareholder letter is available on our website [www.onxeo.com](http://www.onxeo.com) (Media or Investors/Shareholders).*

### **About Onxeo**

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to “make the difference”. The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives.

### ***Key orphan oncology products at the advanced development stage are:***

Livatag® (doxorubicin Transdrug™): Phase III in hepatocellular carcinoma

Validive® (clonidine Lauriad®): Phase II in severe oral mucositis: Positive final results

Beleodaq® (belinostat): registered in the US in 2<sup>nd</sup> line treatment of peripheral T-cell lymphoma

*For more information, visit the website [www.onxeo.com](http://www.onxeo.com)*

**To receive our press releases and newsletters, please register on: <http://www.onxeo.com/en/newsletter/>**

**Follow us on twitter @Onxeo\_**

### **Disclaimer**

*This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2014 Reference Document filed with the AMF on April 14, 2015, which is available on the AMF website (<http://www.amf-france.org>) or on the company's website ([www.onxeo.com](http://www.onxeo.com)).*

### **Contacts :**

Judith Greciet, CEO  
[j.greciet@onxeo.com](mailto:j.greciet@onxeo.com)  
Nicolas Fellmann, CFO  
[n.fellmann@onxeo.com](mailto:n.fellmann@onxeo.com)  
+33 1 45 58 76 00

Caroline Carmagnol and Florence Portejoie  
[onxeo@alizerp.com](mailto:onxeo@alizerp.com)  
+33 6 64 18 99 59 / +33 6 47 38 90 04